cbdMD Expands Regulatory Science Platform for Cannabinoid Evaluation

Got story updates? Submit your updates here. ›

cbdMD, Inc., a leading innovator in hemp-derived wellness products, announced a strategic initiative to integrate and expand its regulatory science, safety, and intellectual property assets. The program combines scientific and regulatory assets acquired through cbdMD's recent acquisition of Bluebird Botanicals with cbdMD's existing clinical and toxicology foundation, creating what the company believes is one of the most comprehensive safety and regulatory dossiers spanning both broad-spectrum and full-spectrum cannabinoid formulations.

Why it matters

As federal regulation and evaluation frameworks for cannabinoid products continue to evolve, cbdMD is proactively building a robust regulatory science platform to engage credibly with regulators, the medical community, and healthcare innovation stakeholders. This positions the company to navigate the emerging regulatory landscape and capitalize on new opportunities.

The details

The acquisition of Bluebird Botanicals brings cbdMD one of the industry's most established safety evaluations for a full-spectrum cannabinoid formulation, with Bluebird's self-affirmed GRAS (Generally Recognized As Safe) determination. cbdMD is now launching an integrated GRAS and regulatory science program to consolidate, modernize, and strengthen its combined science portfolio, primarily through its internal scientific, quality, and regulatory organization.

• In early January 2026, cbdMD acquired substantially all assets of Bluebird Botanicals.
• As part of the strategic initiative, cbdMD is launching the integrated GRAS and regulatory science program.

What they’re saying

What’s next

cbdMD plans to prepare a new self-affirmed GRAS determination for its broad-spectrum formulations and continue strengthening Bluebird's existing full-spectrum GRAS dossier under a unified regulatory strategy.